menu
    • menu
    [{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"AstraZeneca","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ RedHill Biopharma"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daiichi Sankyo \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ RedHill Biopharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ RedHill Biopharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ RedHill Biopharma"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RedHill Biopharma \/ Apotex Inc","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Biopharma \/ Apotex Inc"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"HCR","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu opoid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RedHill Biopharma \/ HCR","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Biopharma \/ HCR"},{"orgOrder":0,"company":"Valinor Pharma","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Naloxegol Oxalate","moa":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Valinor Pharma","amount2":0.25,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0.25,"dosageForm":"","sponsorNew":"Valinor Pharma \/ Grunenthal","highestDevelopmentStatusID":"2","companyTruncated":"Valinor Pharma \/ Grunenthal"}]

    Find Clinical Drug Pipeline Developments & Deals for Naloxegol Oxalate

    Menu

    Naloxegol Oxalate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Valinor Pharma

    U.S.A arrow
    ELCC
    Not Confirmed

    Valinor Pharma

    U.S.A arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Study Phase : Discovery

    Sponsor : Grunenthal

    Deal Size : $250.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Grünenthal Continues US Growth Push with $250M Acquisition of Valinor Pharma

    Details : Through the acquisition, Grunenthal will leverage the Valinor pipeline, which also includes Movantik (naloxegol), indicated for the treatment of OIC in adult patients with chronic non-cancer pain.

    Product Name : Movantik

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    July 22, 2024

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Highest Development Status : Discovery

    Sponsor : Grunenthal

    Deal Size : $250.0 million

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    RedHill Biopharma

    Israel arrow
    ELCC
    Not Confirmed

    RedHill Biopharma

    Israel arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Study Phase : Approved

    Sponsor : HCR

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    RedHill Biopharma Reaches Agreement in Principle with HCR to Extinguish All Debt Obligations in Exchange for M...

    Details : MOVANTIK is the leading Peripherally-Acting Mu-Receptor Opioid antagonist (PAMORA) indicated for the treatment of opioid induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior canc...

    Product Name : Movantik

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    November 14, 2022

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved

    Sponsor : HCR

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    RedHill Biopharma

    Israel arrow
    ELCC
    Not Confirmed

    RedHill Biopharma

    Israel arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    RedHill Biopharma Introduces Three New Movantik Data Analyzes at PAINWeek 2021

    Details : Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete spontaneous bowel movements in the Movantik group vs. placebo were evaluated across high and low opioid dosages.

    Product Name : Movantik

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    September 07, 2021

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    RedHill Biopharma

    Israel arrow
    ELCC
    Not Confirmed

    RedHill Biopharma

    Israel arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Study Phase : Approved

    Sponsor : Apotex Inc

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex

    Details : Under the terms of the settlement agreement, Apotex may not sell a generic version of Movantik in the U.S. until October 1, 2030 (subject to U.S. FDA approval) or earlier under certain circumstances.

    Product Name : Movantik

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    July 22, 2021

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved

    Sponsor : Apotex Inc

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    RedHill Biopharma

    Israel arrow
    ELCC
    Not Confirmed

    RedHill Biopharma

    Israel arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021

    Details : Both analyses included pooled data from two large, robust, identically designed Phase 3 studies of Movantik (Kodiak 4 and Kodiak 5), involving 891 treated patients across two doses (12.5 mg and 25 mg), compared to a total of 546 patients in the placebo a...

    Product Name : Movantik

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    May 24, 2021

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Cosmo Pharmaceuticals

    Ireland arrow
    ELCC
    Not Confirmed

    Cosmo Pharmaceuticals

    Ireland arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Study Phase : Approved

    Sponsor : RedHill Biopharma

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movanti...

    Details : The agreements secure high-quality manufacturing capacity of Movantik® for opioid-induced constipation and RHB-204, currently in a Phase 3 study for pulmonary NTM disease.

    Product Name : Movantik

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    February 18, 2021

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved

    Sponsor : RedHill Biopharma

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    AstraZeneca

    United Kingdom arrow
    ELCC
    Not Confirmed

    AstraZeneca

    United Kingdom arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Study Phase : Approved

    Sponsor : RedHill Biopharma

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca

    Details : RedHill Biopharma has gained the rights to Movantik (naloxegol)1 in Israel from AstraZeneca. RedHill now holds the worldwide rights to Movantik, excluding Europe and Canada. RedHill to evaluate partnering opportunities for commercialization of Movantik i...

    Product Name : Moventig

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    October 08, 2020

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved

    Sponsor : RedHill Biopharma

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Daiichi Sankyo

    Japan arrow
    ELCC
    Not Confirmed

    Daiichi Sankyo

    Japan arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Study Phase : Approved

    Sponsor : RedHill Biopharma

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik®

    Details : RedHill and Daiichi Sankyo replaced their co-commercialization agreement for Movantik® with a new royalty-bearing agreement, under which RedHill will maintain sole and exclusive responsibility for the commercialization of Movantik® in the U.S.

    Product Name : Movantik

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    August 03, 2020

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved

    Sponsor : RedHill Biopharma

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    AstraZeneca

    United Kingdom arrow
    ELCC
    Not Confirmed

    AstraZeneca

    United Kingdom arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Study Phase : Approved

    Sponsor : RedHill Biopharma

    Deal Size : $67.5 million

    Deal Type : Divestment

    DEALS_DEV arrow-down

    AZ licences Movantik rights to RedHill

    Details : In 2015, AstraZeneca entered into a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik in the US, which has now been transferred to RedHill.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : $52.5 million

    April 02, 2020

    Lead Product(s) : Naloxegol Oxalate

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved

    Sponsor : RedHill Biopharma

    Deal Size : $67.5 million

    Deal Type : Divestment

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth